Why the study?
Serial cTnI measurements predict cardiac death better than single measurements in humans, but whether cTnI reflects MMVD severity and serial changes provide prognostic value in canine CHF was unproven.
Does serial measurement of cardiac troponin I predict cardiac death in dogs with congestive heart failure secondary to myxomatous mitral valve disease?
Does serial measurement of cardiac troponin I predict cardiac death in dogs with congestive heart failure secondary to myxomatous mitral valve disease?
In dogs with CHF secondary to MMVD, a downward trend in serial cTnI levels paradoxically indicated a higher risk of cardiac death, suggesting that serial changes may be confounded by medical treatment.
cTnI decline may flag higher cardiac death risk in MMVD-CHF dogs; leaves open serial monitoring value after treatment adjustment.
Serial measurements of cardiac troponin I (cTnI) levels are considered to be better predictors of cardiac death than single-time-point analyses in human medicine. We hypothesised that cTnI levels could reflect the severity of myxomatous mitral valve disease (MMVD), and that serial changes in the cTnI level had a prognostic value in dogs with congestive heart failure (CHF) secondary to MMVD. Seventy-six dogs were initially enrolled and classified by the American College of Veterinary Internal Medicine (ACVIM) staging system. The single-timepoint cTnI concentration in these dogs significantly increased with the ACVIM stage. Twenty-seven dogs with CHF subsequently underwent serial measurement of cTnI levels, and the results showed that those who demonstrated a decrease in cTnI levels from the first to the third visit exhibited a higher risk of cardiac death than did those without such changes (P=0.012). We suspect that the downward trend in cTnI levels may be affected by medical treatment for CHF. In conclusion, although cTnI levels could reflect the severity of MMVD to a certain extent, the serial changes may be affected by medical treatment. Therefore, caution should be exercised when cTnI is used for assessment of the prognosis of CHF secondary to MMVD in dogs.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: